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ABSTRACT
Malignant mesothelioma (MM) is a primary tumor arising from the serous 
membranes. The resistance of MM patients to conventional therapies, and the poor 
patients’ survival, encouraged the identification of molecular targets for MM treatment. 
Curcumin (CUR) is a “multifunctional drug”. We explored the in vitro effects of CUR 
on cell proliferation, cell cycle regulation, pro-survival signaling pathways, apoptosis, 
autophagy of human (MM-B1, H-Meso-1, MM-F1), and mouse (#40a) MM cells. In 
addition, we evaluated the in vivo anti-tumor activities of CUR in C57BL/6 mice 
intraperitoneally transplanted with #40a cells forming ascites.
CUR in vitro inhibited MM cells survival in a dose- and time-dependent manner and 
increased reactive oxygen species’intracellular production and induced DNA damage. 
CUR triggered autophagic flux, but the process was then blocked and was coincident with 
caspase 8 activation which activates apoptosis. CUR-mediated apoptosis was supported 
by the increase of Bax/Bcl-2 ratio, increase of p53 expression, activation of caspase 9, 
cleavage of PARP-1, increase of the percentage of cells in the sub G1 phase which was 
reduced (MM-F1 and #40a) or abolished (MM-B1 and H-Meso-1) after MM cells incubation 
with the apoptosis inhibitor Z-VAD-FMK. CUR treatment stimulated the phosphorylation 
of ERK1/2 and p38 MAPK, inhibited that of p54 JNK and AKT, increased c-Jun expression 
and phosphorylation and prevented NF-κB nuclear translocation. Intraperitoneal 
administration of CUR increased the median survival of C57BL/6 mice intraperitoneally 
transplanted with #40a cells and reduced the risk of developing tumors. Our findings 
may have important implications for the design of MM treatment using CUR.
INTRODUCTION
Malignant mesothelioma (MM) is a primary tumor 
arising from the mesothelial cell linings of the serous 
membranes, most commonly involving the pleural and 
peritoneal spaces [1]. MM generally presents as an 
epithelioid phenotype, although biphasic or sarcomatoid 
phenotypes can occur [2-3]. Mesothelium carcinogenesis 
is a multi-step process arising from genetic alterations 
that drive the progressive transformation of normal 
mesothelial cells into MM [4]. The development of 
MM has been linked to the exposure to asbestos causing 
random chromosome breaks [5]. Asbestos fibers can also 
induce non-genotoxic damages, including the abnormal 
activation of the AP-1/TNF-α/NF-κB autocrine pathway, 
which increases cell survival after DNA damage and 
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promotes uncontrolled cell growth [6]. After the fibers’ 
damage to the mesothelium integrity, macrophages 
are activated in an attempt to remove the fibers [6-8]. 
These events trigger a long-lasting inflammation, which 
can enhance DNA damage for the production of free 
radicals and inflammatory cytokines [9]. The long-lasting 
inflammation caused by MM and the poor response to 
therapeutics might be due to the ability of MM cells to 
subvert host immune response [10, 11]. The knowledge 
of MM pathophysiology might influence MM patients 
therapy and survival [4, 12-14]. However, despite this 
knowledge, the MM patients’ survival is poor, and was 
slowly improving in the last decades [15]. Recently, the 
application of hyperthermic intraperitoneal chemotherapy 
(HIPEC) and cytoreductive surgery, had increased 
MM patients’ survival in particular for peritoneal 
mesothelioma [12]. However, the therapeutic strategies 
for the treatment of malignant pleural mesothelioma 
are referred to as ‘life-extending treatments’ [16]. The 
drugs employed over the past decades have shown 
poor response rate (RR), often no higher than 20% 
[16]. The resistance of MM to conventional therapies, 
and the poor patient survival following traditional 
chemotherapy, have supported the identification of novel 
molecular targets for MM treatment. Preclinical studies 
have employed a second generation of drugs including 
inhibitors of mTOR, folate, receptor tyrosine kinase and 
ciclooxygenase [16]. Clinical trials have been performed 
using chemotherapy with proteasome, mTOR and histone 
deacetylases inhibitors [16]. However, although targeted 
therapies improved the patients’ quality of the life and 
survival and the new generation of folate inhibitors alone 
or in combination with platinum derivatives, produced 
encouraging results, the absolute RRs continued to be 
limited compared to other tumors [16]. Accordingly, 
since cancer cells show aberrant signaling pathways, it 
might be important to employ compounds that are able to 
target these multiple abnormally activated transduction 
pathways. Polyphenols can be employed to inhibit the 
growth of cancer cells due to their ability to down-
regulate or block the activity of multiple targets involved 
in carcinogenesis [17-21]. Curcumin (CUR) CUR [l,7-
bis-(4-hydroxy-3-methoxyphenyl)-l,6-heptadiene-3,5-
dione], is a non-flavonoid polyphenol found in the plant 
Curcuma longa, widely employed as a food additive as 
well as in cosmetic and herbal medicine in Asia [22-25]. 
Due to its ability to modulate the activity of multiple 
targets involved in carcinogenesis, CUR is considered 
a “multifunctional drug” [22-25]. Few reports described 
the use of CUR to inhibit the growth of MM cells. CUR 
induced cell death by pyroptosis in mouse and human 
malignant mesothelioma cells [26]. Yamauchi et al. 
reported that CUR induced autophagy in ACC-MESO-1 
cells [27]. In addition, Mayol et al. reported that CUR 
loaded PLGA-poloxamer blend nanoparticles induced 
cell cycle arrest in MM cells [28]. Only two reports 
investigated the in vivo effect of CUR on solid tumor 
burden in mouse models of MM [26, 29]. Little is known 
about the effect of CUR on signal transduction pathways 
activated in MM cells and on the in vivo growth of MM 
cells. Thus, it would be essential to further investigate 
the in vivo effect of CUR in a mouse model in which MM 
cells induce ascites in the peritoneal space.
In this report, we explored the in vitro effects of 
CUR on cell proliferation, cell cycle regulation, pro-
survival signaling pathways, apoptosis and autophagy 
in human and mouse MM cell lines. In addition, we 
evaluated the in vivo antitumor activities of CUR in 
C57BL/6 mice intraperitoneally transplanted with mouse 
MM cells inducing ascites.
RESULTS
Curcumin inhibits human and mouse MM cells 
survival
The survival of human (MM-B1, H-Meso-1, MM-
F1) and mouse (#40a) MM cells was evaluated by the 
SRB assay after exposure to increasing doses of CUR 
(6.25-12.5-25-50 µM) or vehicle control (DMSO) for 
24, 48 and 72 hours (Figure 1). The effect of CUR on 
cell proliferation was dose- and time-dependent and was 
significant compared with that of the vehicle control at 
higher doses. CUR treatment of the MM-B1, MM-F1 and 
the #40a cell lines for 72 hours was able to significantly 
inhibit MM cell growth even at the lowest concentration 
(Figure 1).
The concentration of the compound that inhibits 
50% of cell growth (IC50) was also determined. The 
concentrations of CUR required to reduce cell survival by 
50% after 48 and 72 hours were 28.85 and 25.73 μM for 
MM-B1, respectively; 22.21 and 18.38 μM for H-Meso-1, 
respectively; 29.45 and 30.47 μM for MM-F1, respectively 
and 33.13 and 40.92 for #40a, respectively (Table 1).
Curcumin induces reactive oxygen species (ROS) 
generation in MM cells
One of the major detrimental effects of CUR 
on cancer cells is its ability to increase ROS [30, 31]. 
To determine the effect of CUR on intracellular ROS 
production, the DCF-DA assay was performed in 
CUR-treated MM cells. The effects of the compound 
were compared to those of DMSO and the results were 
expressed as the mean of the fluorescence intensity (Table 
2). CUR induced a significant dose-dependent ROS 
production as compared to the vehicle in all MM cells.
ROS generation is supposed to cause DNA damage 
that rapidly results in the phosphorylation of the histone 
H2A variant (H2AX) at Ser 139 (γ-H2AX) [32, 33]. 
Treatment with CUR at the concentration of 25 μM for 
30 hours led to a significant increased phosphorylation of 
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γ-H2AX in all MM cell lines (MM-F1, p<0.01; MM-B1, 
p<0.001; H-Meso-1, p<0.001; #40a, p<0.01) (Figure 2).
Curcumin increases p62 expression, impairs the 
autophagic flux and activates apoptosis in MM 
cells
Reactive oxygen species (ROS) are the main 
intracellular signal transducers sustaining autophagy 
[34] whose activation can be revealed by the conversion 
of LC3-I in LC3-II. MM cells were treated with 25μM 
CUR or DMSO for 24 hours (Figure 3, Panel A). LC3-I 
and LC3-II were constitutively expressed in DMSO-
treated cells. CUR induced a significant increase of 
LC3-I in all cells (MM-F1, p=0.0009; MM-B1, p=0.002; 
H-Meso-1, p=0.002; #40a, p=0.03). However the increase 
of LC3-I was not paralleled by a significant increase of 
LC3-II except for MM-B1 cells (p=0.003) that showed 
a significant increase of Beclin-1 as well (p=0.002). The 
likelihood of cancer cells toward autophagy or apoptosis is 
dependent on p62 expression. CUR induced a significant 
increase of p62 in all MM cell lines as detected by western 
blotting (MM-F1, p=0.004; MM-B1, p=0.02; H-Meso-1, 
p=0.002; #40a, p=0.004) (Figure 3, Panel A). The increase 
of p62 in CUR-treated MM cell lines was corroborated by 
immunofluorescence analysis (Figure 3, Panel B). These 
results indicated that CUR triggered autophagy but that 
the process was then blocked as revealed by the increase 
of p62.
Autophagy reflects the ability of the cell to adapt to 
stress. However, if the stress is too powerful, the process 
of autophagy is bypassed and apoptosis is activated [35]. 
The increase of p53 represses the autophagy and activates 
multiple pro-apoptotic genes [35]. Thus, p53 and Bax/
Bcl-2 expression was analyzed by western blotting after 
MM cells treatment with 25 µM CUR or DMSO for 24 
hours. CUR treatment increased the Bax/Bcl-2 ratio in 
MM cell lines compared to DMSO treatment (MM-F1, 
p=0.001; MM-B1, p=0.007; H-Meso-1, p=0.002; #40a, 
p=0.01) (Figure 4, Panel A). In addition, CUR increased 
Figure 1: Effect of CUR on MM cell lines survival. The survival of human (MM-B1, H-Meso-1, MM-F1) and mouse (#40a) cell 
lines was assessed by the SRB assay after 24, 48 and 72 hours of treatment with DMSO or CUR. The percentage of surviving cells treated 
with the compound was calculated by normalizing the O.D. value to that of the control cultures (DMSO). The results are expressed as the 
means ± SD of three independent experiments performed in triplicate (xp ≤ 0.05, *p ≤ 0.01, #p ≤ 0.001 compared with the cultures treated 
with DMSO).
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Table 2: Effects of CUR on the intracellular ROS production in MM cell lines
MM-B1 H-Meso-1 MM-F1 #40a
Mean±SDa p Mean±SD p Mean±SD p Mean±SD p
DMSO 3744±212 4223±119 5580±31 3234±307
CUR 6.25 4362±185 4817±104 5680±42 3724±709
CUR 12.5 4674±314 5771±708 <0.001 6485±119 <0.001 5550±197 <0.01
CUR 25 7762±561 <0.001 6057±586 <0.001 7147±120 <0.001 7437±1322 <0.001
CUR 50 9263±931 <0.001 6328±343 <0.001 7121±61 <0.001 8150±1176 <0.001
aThe results are reported as the mean of the fluorescence intensity ± SD values from three experiments performed in 
triplicate. CUR was used in the range 6.25-50 μM. The statistical significance of the effect of CUR was calculated vs. that 
of DMSO.
Figure 2: Effect of CUR on DNA damage in MM cells. The expression of γ-H2AX was assessed by western blotting in MM cell 
lines treated with CUR at 25 μM or with DMSO for 24 and 30 hours. Actin was used as an internal control. The intensity of the bands was 
quantified using the ImageJ software after blot scanning of two independent experiments. The densitometric ratios between γ-H2AX and 
actin are reported.
Table 1: CUR concentration required for 50% inhibition of MM cell lines survival (IC50)
MM cell lines CUR treatment (hours) IC50 (µM) ± SD
MM-B1
48 28.85 ± 1.40
72 25.73 ± 1.53
H-Meso-1
48 22.21 ± 1.39
72 18.38 ± 0.20
MM-F1
48 29.45 ± 0.83
72 30.47 ± 3.68
#40a
48 33.13 ± 4.18
72 40.92 ± 4.42
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p53 expression compared to DMSO treatment in MM-F1 
(p=0.012), MM-B1 (p=0.028), and H-Meso-1 (p=0.005) 
cells (Figure 4, Panel A). The activation of the intrinsic 
pathway of the apoptosis is sustained by the activation 
of the procaspase 9 into caspase 9. CUR was able to 
induce the activation of procaspase 9 in MM-B1 and #40a 
cells as detected by the appearance of a low molecular 
weight fragment of about 35 kDa, corresponding to the 
active caspase 9. Moreover CUR decreased procaspase 9 
expression in MM-B1 and H-Meso-1 cells as compared to 
DMSO treated cells (ratio 0.64 vs 0.31 and 1.58 vs 0.52 
respectively, p<0.05), thus suggesting the activation of the 
molecule [36] (Figure 4, Panel A).
In addition, we determined whether CUR was able 
to activate apoptosis through the extrinsic pathway as 
well. CUR activated procaspase 8 as detected in western 
blotting by the presence of caspase 8 cleavage fragments 
(p43/41 or p18) in human MM cells (Figure 4, Panel A).
Finally, MM cells were labeled with an anti-
activated caspase 3 polyclonal antibody after treatment 
with CUR (25 μM) or DMSO for 24 hours or, as positive 
control, with staurosporine (1 μM) for 16 hours. Figure 4, 
Panel B shows a representative experiment. According to 
activated caspase 3 positivity, the treatment with DMSO 
had no effect on the induction of apoptosis in MM-F1 
(0.006%), MM-B1 (0.006%), H-Meso-1 (0.004%) and 
#40a cells (0.007%) (Figure 4, Panel B). Conversely, the 
percentage of apoptotic CUR-treated cells was 46% for 
MM-F1 (p<0.001), 29% for MM-B1 (p<0.001), 53% for 
H-Meso-1 (p<0.001) and 34% for #40a cells (p<0.001). 
Treatment with staurosporine resulted in apoptotic rates 
of 85% for MM-F1, 79% for MM-B1, 88% for H-Meso-1 
and 81% for #40a cells (Figure 4, Panel B).
Caspase 3 cleaves poly (ADP-ribose) polymerase-1 
(PARP-1) thereby inactivating it and impairing DNA 
repair and genomic integrity [37]. CUR-mediated cleavage 
of PARP-1 was determined by western blotting (Figure 4, 
Panel C). CUR treatment resulted in considerable PARP-1 
proteolytic cleavage in all MM cells (Figure 4, Panel C). 
To further corroborate CUR-mediated apoptosis of MM 
cells, FACS analysis of DNA content was performed. 
Figure 5 shows a representative experiment in which 
the effects of increasing doses of CUR were compared 
to those obtained with DMSO vehicle only. Our results 
demonstrate that CUR induced an increase in the 
percentage of cells in the sub G1 phase in all MM cell 
lines at the higher dose (Table 3). To confirm the effect 
of CUR in inducing MM cells apoptosis, MM cells were 
simultaneously exposed to CUR and to the Z-VAD-FMK, 
a universal inhibitor of caspases. Z-VAD-FMK was able 
to significantly reduce CUR-mediated apoptosis in MM-
F1 and #40a cells and abolish it in MM-B1 and H-Meso-1 
cell lines (Table 3, Figure 5). The increase in the sub G1 
phase mediated by CUR was associated to the increase in 
Figure 3: Effect of CUR on the autophagic flux in MM cells. Panel A. The expression of Beclin-1, LC3-I and LC3-II, and p62 
was assessed by western blotting in MM cell lines treated with CUR at 25 μM or DMSO for 24 hours. Actin was used as an internal control. 
The intensity of the bands was quantified using the ImageJ software after blot scanning of two independent experiments. The densitometric 
ratios between Beclin-1 and actin, LC3-I and actin, LC3-II and actin, p62 and actin are reported. Panel B. The expression of p62 after 
treatment with CUR in MM cells was determined by immunofluorescence analysis. Cells were fixed after treatment, and incubated with the 
anti-p62 antibody. After two washes with PBS, cells were incubated with the secondary Alexa fluor-594-conjugated goat anti-rabbit IgG 
antibody. Nuclei were stained with Hoechst. Original magnification x400. n.d= not detectable.
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Figure 4: Effect of CUR on apoptosis in MM cells. Panel A. The expression of Bax, Bcl-2, p53, procaspases (9 and 8) and caspases 
(9 and 8) was assessed by western blotting analysis in MM cells treated for 24 hours with CUR at 25 μM or with DMSO as vehicle. 
Actin was used as an internal control. The intensity of the bands was quantified using ImageJ software after blot scanning, obtained from 
two independent experiments. The densitometric ratios between Bax and Bcl-2, and between p53 and actin are reported. Panel B. The 
expression of active caspase 3 in MM cells treated with CUR at 25μM for 24 hours was determined by immunofluorescence analysis. Cells 
were fixed after treatment and incubated with the anti-cleaved caspase 3 antibody. After two washes with PBS, cells were incubated with 
the secondary Alexa fluor-594-conjugated goat anti-rabbit IgG antibody. Nuclei were stained with Hoechst. Staurosporine at 1 μM for 16 
hours was used as positive control of apoptosis. Original magnification x200 and x400. Panel C. The cleavage of PARP-1 in CUR-treated 
MM cells. Western blotting was performed on cells treated with a concentration of 25 μM of CUR or the DMSO vehicle for 24 h. Actin 
was used as an internal control.
Figure 5: Effect of CUR on cell cycle distribution. FACS analysis of DNA content was performed on asynchronized log phase 
growing MM cell lines treated for 48 hours with DMSO, CUR at 25, 12.5, 6.25 μM, or CUR + Z-VAD. Z-VAD-FMK (Z-VAD) is a 
universal inhibitor of caspases. A representative experiment is shown.
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the G2/M and to the decrease of the G0/G1 phases in all 
human cell lines. The increase in the sub G1 phase was 
associated to a decrease of the G0/G1 phase at the dose of 
25 µM in the mouse cell line (Table 3).
Curcumin increases the phosphorylation 
of ERK1/ERK2 and p38 but abolishes or 
diminishes that of JNK and AKT
It has been reported that asbestos fibers are able to 
activate EGFR in mesothelial cells, an event associated 
to the activation of the downstream extracellular signal-
regulated kinases (ERKs) [38]. Thus, we evaluated the 
expression and phosphorylation of mitogen-activated 
protein (MAP) kinases including ERK1/2, the p38 kinase 
and the c-Jun N-terminal kinases (JNKs p54 and p46) upon 
CUR treatment (Figure 6). The levels of phosphorylated 
proteins were compared with the total proteins level. As 
shown in Figure 6, treatment with CUR increased the 
level of phosphorylation of ERK1 in MM-F1 (p=0.004), 
MM-B1 (p=0.017), and #40a (p=0.0004) cells compared 
to DMSO-treated cells. CUR treatment increased 
Table 3: Effects of Curcumin (CUR) alone or with the inhibitor of apoptosis Z-VAD-FMK on cell cycle distribution 
in MM cell lines after 48 hours of treatment
μM Sub 
G1a
p* G0/G1 p S p G2/M p
MM-B1 DMSO 6.56 68.12 7.40 18.28
CUR 6.25 4.96 NS 69.12 NS 8.64 NS 17.68 NS
CUR 12.5 6.33
 
NS 64.81 NS 10.97 NS 19.39 NS
CUR 25 36.05 p<0.001 26.42 p<0.001 11.20 NS 26.70 p<0.05
CUR25+Z-
VAD
6.18 p<0.001 24.78 NS 17.06 p<0.001 52.50 p<0.001
H-Meso-1 DMSO 2.20 59.24 9.85 29.18
CUR 6.25 7.39 NS 48.82 NS 9.00 NS 35.24 NS
CUR 12.5 6.38 NS 60.22 NS 12.50 NS 21.51 NS
CUR 25 15.09 p<0.01 29.19 p<0.01 10.39 NS 45.84 p<0.05
CUR25+Z-
VAD
4.50 p<0.05 51.34 p<0.05 11.17 NS 33.50 NS
MM-F1 DMSO 2.16 81.76 4.46 10.84
CUR 6.25 2.27 NS 80.26 NS 5.84 NS 11.92 NS
CUR 12.5 4.36 NS 75.47 NS 6.66 NS 13.85 NS
CUR 25 49.05 p<0.001 28.03 p<0.001 5.55 NS 17.58 p<0.05
CUR25+Z-
VAD
10.30 p<0.001 40.79 p<0.01 11.56 p<0.05 37.81 p<0.001
#40a DMSO 5.63 56.98 6.96 30.60
CUR 6.25 6.75 NS 61.98 NS 8.17 NS 23.38 NS
CUR 12.5 8.18 NS 40.92 p<0.01 18.78 p<0.01 32.61 NS
CUR 25 48.24 p<0.001 11.07 p<0.001 15.76 p<0.05 25.30 NS
CUR25+Z-
VAD
18.33 p<0.001 13.59 NS 26.83 p<0.001 41.73 p<0.05
a Percentage of cells in sub G1, G0/G1, S and G2/M phases was calculated with CellQuest Pro 5.2 software. The results 
reported are mean values from three independent experiments. * Significance of the effect of CUR was calculated vs. 
that of DMSO treated cells with one-way ANOVA analysis of variance. Significance of the effect of CUR25+Z-VAD was 
calculated vs. that of CUR 25 employing the Student’s t-test.
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phosphorylation of ERK2 in MM-F1 (p=0.0002), MM-B1 
(p=0.028), H-Meso-1 (p=0.007), and #40a (p=0.001) cells. 
p38 phosphorylation was increased upon CUR treatment 
in all MM cells (Figure 6). On the other hand, p54 JNK 
phosphorylation was abolished in all MM cell lines, while 
p46 JNK phosphorylation was decreased in MM-B1 
(p=0.014), H-Meso-1(p=0.003) and #40a (p=0.0007) cells 
(Figure 6). Furthermore, CUR significantly increased the 
expression of c-Jun in all MM cell lines as compared to 
DMSO treated cells (MM-F1, p=0.001; MM-B1, p=0.05; 
H-Meso-1, p=0.02; #40a, p<0.0001). The increased 
expression of c-Jun was paralleled by the increase of its 
phosphorylation (MM-F1, p=0.001; MM-B1, p=0.01; 
H-Meso-1, p=0.001; #40a, p=0.0001) (Figure 6).
Figure 6: Effect of CUR on the expression and activation of signaling pathway molecules. Western blotting analysis was 
performed on MM cells treated with CUR (25 μM) or DMSO vehicle for 24 hours. The levels of pERK1 and pERK2 proteins, as well as 
p-p38 protein, pJNK, p-c-Jun and pAKT proteins were compared with that of total ERK, p38, JNK, c-Jun and AKT proteins, respectively. 
The ratios are reported. Actin and tubulin were used as an internal control. n.d= not detectable.
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In addition, we evaluated whether CUR treatment 
inhibited the expression and phosphorylation of the pro-
survival kinase AKT, which promotes tumor growth. CUR 
treatment abolished AKT phosphorylation in MM-F1 and 
MM-B1 and slightly reduced it in H-Meso-1 (p=0.047), 
and #40a (p=0.024) cells (Figure 6).
Curcumin inhibits NF-κB nuclear translocation 
in MM cells
It was reported that JNK is able to mediate activation 
of NF-κB [39]. Thus, we determined whether CUR was 
able to modulate NF-κB activation in MM cells. Treatment 
with CUR did not affect the expression of NF-κB in MM 
cells as revealed by western blotting analysis (Figure 
7, Panel A). NF-κB functions as a transcription factor, 
moving into its active form in the nucleus. To determine 
if CUR treatment was able to affect NF-κB nuclear 
translocation, the NF-κB localization was analyzed by 
immunofluorescence analysis (Figure 7, Panel B). NF-κB 
was found to be mainly localized in the nucleus in DMSO-
MM-treated cells. Conversely, CUR treatment induced the 
accumulation of NF-κB in the cytoplasm of all MM cell 
lines, thus indicating an inhibitory effect of CUR on NF-
κB nuclear translocation (Figure 7, Panel B).
Curcumin reduces tumor growth in C57BL/6 
mice intraperitoneally transplanted with MM 
#40a cells
To evaluate the in vivo antitumor effects of CUR, 
C57BL/6 mice (6 mice per group) were intraperitoneally 
inoculated with 1x106 #40a cells. These mice were 
simultaneously intraperitoneally administered with 1.5 
mg of CUR dissolved in corn oil or with the vehicle 
alone. The treatment was performed once a week. To 
Figure 7: Effect of CUR on NF-κB expression and localization. Panel A. Western blotting analysis was performed on MM cells 
treated with CUR at 25 μM or with the DMSO vehicle for 24 hours. The densitometric ratio between NF-κB and actin is reported. Panel 
B. Inhibition of nuclear translocation of NF-κB after treatment with CUR in MM cells was assessed by immunofluorescence analysis. 
Cells were fixed after treatment, and incubated with the anti-NF-κB antibody. After two washes with PBS, the cells were incubated with 
the secondary Alexa fluor-488-conjugated goat anti-mouse IgG antibody. Nuclei were stained with DAPI. Original magnification x400.
Oncotarget34414www.impactjournals.com/oncotarget
monitor the growth of #40a cells which induced ascites, 
the measurement of the abdominal circumference of the 
mice was assessed prior to cells inoculation and then 
every week. After 3 weeks of treatment, mice treated 
with CUR showed a significant decrease in the abdominal 
circumference compared to control mice (mean value 9.3 
cm compared with 12.5 cm, p=0.0008) (Figure 8, Panel 
A). At this stage, control mice were euthanized because 
of the excessive size of their tumors. Conversely, 2 and 
3 CUR-treated mice were euthanized after 4 and 5 weeks 
of treatment, respectively. Only one CUR-treated mouse 
was still alive after ten weeks (abdominal circumference 
equal to 8.0 cm) when the experiment was completed. The 
increase in the median survival of CUR-treated mice was 
significant compared to vehicle-treated mice (p=0.0009) 
(Figure 8, Panel B). The risk of developing tumors in 
the corn oil-treated mice was 39.12 relative to the CUR-
treated mice (Table 4).
Overall, our results indicated specific interference 
with intraperitoneally transplanted MM #40a cells growth 
by CUR.
DISCUSSION
The poor bioavailability of anti-cancer agents at 
the tumor sites affects the efficacy of chemotherapeutic 
treatments. In addition, the majority of the anti-cancer 
drugs does not achieve an effective concentration in the 
tumor [40]. Intratumoral drug delivery might facilitate 
the presence of a high concentration of the drug within 
the tumor and avoid the onset of side effects. This 
scenario becomes particularly interesting when the 
treatment can be applied to outside accessible tumors, 
including breast, head and neck, bladder cancers and 
mesothelioma.
Thus, the local administration of drugs in the serous 
cavity might be an improved strategy to treat MM [1]. 
Among the others, the polyphenol curcumin was shown to 
inhibit cancer cell growth by targeting multiple signaling 
pathways [24, 25, 29]. Clinical and preclinical studies 
have been demonstrated that CUR administration is safe 
[41]. The pharmacological potential of CUR is severely 
restricted due to its short half-life, poor bioavailability, 
low water solubility and absorption [42, 43]. Accordingly, 
we evaluated the in vitro and in vivo effects of CUR 
administration in MM cells. Our data demonstrated that 
treatment of MM cell lines with CUR was able to in 
vitro inhibit cells survival in a dose- and time-dependent 
manner. The inhibition of MM cells survival was paralleled 
by the increase of ROS intracellular production. CUR can 
function as an anti-oxidant or a pro-oxidant drug [31]. Low 
levels of ROS might induce cell proliferation and survival, 
while increased levels of ROS might induce autophagy 
and apoptosis by damaging DNA, proteins, and lipids 
[44]. DNA damage rapidly results in the phosphorylation 
of histone H2A variant (H2AX) at Ser 139 (γ-H2AX) [32, 
33]. Our results demonstrated that treatment with CUR 
led to a significant increased phosphorylation of γ-H2AX 
in all the MM cell lines thus indicating CUR-mediated 
DNA damage. Oxidative stress is also a potent inducer 
of autophagy and apoptosis [44]. Thus, we next analyzed 
the ability of CUR treatment to induce autophagy in 
MM cell lines. Previous reports have demonstrated that 
CUR induces autophagy in several cancer cell lines [45]. 
CUR treatment was able to induce an increase in LC3-II/
LC3-I ratio and autophagosome formation in the human 
malignant pleural mesothelioma ACC-MESO-1 cell line 
as well [27]. However, our results demonstrated that 
CUR treatment was able to trigger autophagy but that the 
autophagic flux was blocked as revealed by the increase 
Figure 8: CUR reduced tumor growth and increased the survival in C57BL/6 mice intraperitoneally transplanted with 
MM #40a cells. Panel A. Differences in mean tumor volumes between C57BL/6 mice treated with CUR or with corn oil (CTRL). Panel 
B. Differences in the mean survival time of C57BL/6 mice treated with CUR or with corn oil (CTRL). The numbers of inoculated mice are 
reported in the “Materials and Methods”.
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of p62/SQSMT1. p62/SQSMT1 is a scaffold protein 
regulating signaling pathways involved in cell growth and 
proliferation. The levels of p62 usually inversely correlate 
with autophagic degradation [46]. Autophagy could be 
a pro-survival response for different tumors after anti-
cancer treatments [47]. However, if the intensity or extent 
of cellular stress exceed the ability of the cells to repair 
the damages, the autophagy is inhibited and apoptosis 
is activated. Thus, autophagy often precedes apoptosis 
after cancer cells treatment with chemotherapeutic agents 
[35, 48]. p62/SQSMT1 is involved in the regulation of 
apoptosis by activating caspase 8 [49]. When autophagy 
is inhibited, caspase 8 dependent cell death is paralleled 
by the increase of p62 in cancer cells [50]. Here, we 
demonstrated that the inhibition of the autophagic flux 
triggered by CUR treatment and associated with the 
increased expression and cytoplasmic accumulation of 
p62, was also coincident with the activation of caspase 
8 which activates the extrinsic apoptotic pathway. The 
activation of the extrinsic apoptotic pathway mediated 
by CUR treatment through Fas receptor activation, was 
previously established in other cancer cell lines [51-54]. 
Apoptosis can be also activated by oxidative stress-
induced DNA damage, which activates p53 and different 
signal transducers such as p38, ERK and JNK [55]. p53 is 
a key regulators of the cell fate. DNA damage dramatically 
increases p53 expression and activation and cell cycle 
arrest and, if the DNA cannot be repaired, it activates the 
intrinsic apoptotic pathway [56]. Our results demonstrated 
that CUR treatment increased the Bax/Bcl-2 ratio in all 
MM cell lines by downregulating the expression of Bcl-2 
and by upregulating the expression of Bax. In addition, 
CUR induced the increase of p53 expression and the 
activation of caspase 9, thus suggesting activation of the 
intrinsic pathway of apoptosis. Although p53 mutations 
are rare in MM, the loss of p14 in MM cells might result in 
the activation of the mdm2 protein and p53 destabilization 
[57]. Thus, it is of note that CUR upregulated p53 
expression in MM cells. We also demonstrated that the 
activated caspase 3 cleaved PARP-1 thus corroborating 
that the inhibition of cell survival exerted by CUR 
treatment is mainly mediated by apoptosis. This result 
was corroborated by the incubation of MM cell lines with 
the specific inhibitor of apoptosis Z-VAD-FMK. Indeed, 
Z-VAD-FMK was able to significantly reduce and in MM-
B1 and H-Meso-1 cell lines abolish the CUR-mediated 
MM cells apoptosis.
Some natural compounds, including resveratrol, 
quercetin and apigenin, require MAPKs activation, 
in particular ERK1/2 activation, for the induction of 
apoptosis [58]. In addition, oxidative stress is responsible 
for activation of MAPKs and p38 is important for ROS-
mediated apoptosis [59]. Our results demonstrated that 
CUR treatment stimulated the phosphorylation of both 
ERK1/2 and p38 MAPK in all the examined MM cell 
lines. Of note, CUR inhibited p54 JNK phosphorylation 
while that of p46 JNK was only partly affected in 
H-Meso-1 and #40a cell lines. In addition, CUR inhibited 
AKT phosphorylation and NF-κB nuclear translocation. 
CUR inhibition of NF-κB and AKT signaling could 
prevent pro-survival signals thus inducing apoptosis [60]. 
It was reported that treatment of malignant pleural MM 
cell lines with butein interfered with the stability of the 
STAT3-NF-κB and decreased chemoresistance in vitro and 
in vivo [61, 62]. AKT activation has been demonstrated 
in malignant pleural mesothelioma specimens and PI3K/
mTOR inhibitors significantly suppressed malignant 
pleural mesothelioma cell growth [63].
CUR-mediated apoptosis was dependent on JNK 
and p38 activation in colon cancer cell lines [64]. JNK 
and p38 may function in a cell type-specific manner to 
modulate intracellular signals that regulate proliferation, 
differentiation, survival and death. JNK and p38 can 
have antagonist effects. p38 activation is normally 
associated with anti-proliferative functions and in some 
cases can negatively regulate JNK activity in different 
cell types [65]. Recent studies have shown that p38 and 
JNK have a key role in the crosstalk between autophagy 
and apoptosis induced by DNA damage [66]. Moreover, 
it has been reported that JNK activation stimulates the 
autophagy by interfering with Bcl-2/Beclin interaction 
and that the pharmacological inhibition of JNK causes 
accumulation of p62 and reduces the LC3II/LC3I ratio 
flux and activates caspase 3. In particular, p54 JNK 
phosphorylation may support cell survival during 
cellular stress, while viral infections such as Kaposi 
sarcoma-associated herpes virus infections are able 
to inhibit p54 JNK phosphorylation, thus inhibiting 
Table 4: Analysis of the survival of C57BL/6 mice after treatment with CUR by the log-rank test (Mantel-Cox)
Variable Contrast Hazard Ratio
95%Hazard Ratio Confidence 
Limits p Value
Median 
Survival 
(Weeks)
Lower Upper
Treatment CUR vs Corn Oil 39.12 4.481 341.6 0.0009 5 vs 3
Mice were treated with CUR or corn oil.
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autophagy and reducing cell survival [67-69]. In 
agreement with these results, the inhibition of p54 JNK 
phosphorylation by CUR further supports the block 
of the autophagic flux and the induction of apoptosis 
in MM cells. CUR-mediated activation and then 
impairment of autophagy and activation of apoptosis 
observed in MM cell lines could be due to the activation 
of ERK1/2 and p38 signaling, the last items responsible 
for the JNK inhibition.
c-Jun is an early response transcription factor that 
can be induced by DNA damage. Indeed, ERK activation 
is able to increase the expression of c-Jun by enhancing its 
stability. Phosphorylation of c-Jun is mainly mediated by 
JNK, but alternative pathways for c-Jun activation have 
been described [70, 71]. CUR increased the expression 
and phosphorylation of c-Jun in MM cells despite the 
inhibition of JNK, thus suggesting the activation of 
an alternative pathway for c-Jun phosphorylation. The 
increased expression of c-Jun upon CUR treatment might 
be due to activation of ERK [70].
Few studies have analysed the in vivo effect of 
CUR on MM cells growth. Miller et al. reported that 
daily oral administration of CUR via gavage (500 mg/
kg and 2 g/kg) or three intraperitoneal injections of CUR 
(100-200 mg/kg) were not able to reduce the growth of 
#40 cells growing as a solid tumor in the peritoneal 
cavity [26]. Wang et al. analyzed the effect of daily 
administration of 500 mg/kg CUR by oral gavage in 
BALB/c mice subcutaneously inoculated with AB12 MM 
cells. They showed that CUR administration suppressed 
solid tumor growth [29]. Here, we demonstrated that 
the intraperitoneal administration of CUR reduced 
peritoneal #40a cells growth in C57BL/6 mice. The #40a 
cell line, when transplanted in the peritoneal cavity, is 
able to reproducibly induce ascites in C57BL/6 mice. 
Thus, the effect of CUR administration was revealed 
by measuring the abdominal circumference of the mice. 
Overall, the risk of developing tumors in the corn oil 
treated mice was 39.12 in comparison to those treated 
with 75 mg/kg CUR one time per week. In addition, the 
increase in the median survival of mice administered 
with CUR was superior to that of mice receiving corn 
oil. MM is an aggressive tumor. The ability of CUR to 
in vivo interfere with MM cell growth might offer an 
additional tool for MM treatment. The administration 
of CUR in the peritoneal space allows the increase of 
CUR concentration to which cancer cells are exposed. In 
addition, CUR is able to modulate the immune response 
[72]. Thus, CUR might potentiate mice immune 
response against MM cells.
Overall, the in vitro and in vivo effects of CUR on 
MM cells are summarized in Figure 9.
Several in vitro and in vivo preclinical studies 
have brought CUR to clinical trials and its safety and 
efficacy has been tested and proved for using it as a 
chemopreventive agent or to be used in combination with 
the conventional chemotherapy [73]. The possibility of 
administering CUR directly to the tumor site could avoid 
the poor CUR bioavailability and potential side effects. 
MM patients survival is poor, although standard therapy 
and the incidence of MM is expected to increase in the 
near future. The possibility of using CUR, analogs of 
CUR or formulations of CUR with slower release of the 
compound at the tumor site could improve the delivery 
of the compound. Our findings may have important 
implications for the design of MM treatment using CUR 
in addition to other drugs.
Figure 9: Overall in vitro and in vivo effects of CUR on MM cells.
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MATERIALS AND METHODS
Reagents
DMSO, Curcumin (CUR), Sulforhodamine B 
(SRB), Hoechst 33342, DAPI and Pristane (2,6,10,14-Te
tramethylpentadecane) were purchased from Sigma 
Aldrich (Milano, Italy). Z-VAD-FMK was purchased 
from Calbiochem (San Diego, CA, USA). Antibodies 
against AKT, phospho-AKT, p38 and phospho-p38, 
JNK and phospho-JNK, caspase 9, caspase 8, activated 
caspase 3, c-Jun and phospho-c-Jun were obtained from 
Cell Signaling Technology (MA, USA). Antibodies 
against Bax, Bcl-2 and γ-H2AX were obtained from 
BD Pharmigen (BD Biosciences, CA, USA). Antibodies 
against p53, PARP-1, ERK1/2 (C-14), phospho-
ERK (E-4), NF-κB (p65) were obtained from Santa 
Cruz Biotechnology (CA, USA). Antibodies against 
Beclin-1 and p62/SQSTM1 were obtained from Abcam 
(Cambridge, UK) and the anti-LC3 antibody was 
purchased from Novus Biologicals (Littleton, CO, 
USA). Goat anti-rabbit IgG Alexa fluor-594-conjugated 
and goat anti-mouse IgG Alexa fluor-488-conjugated 
secondary antibodies were purchased from Invitrogen 
(Milano, Italy). The rabbit polyclonal antibody against 
actin and tubulin and goat anti-mouse or the anti-rabbit 
IgG peroxidase-conjugated secondary antibodies were 
obtained from Sigma-Aldrich.
Cell lines and treatments
Human (MM-B1, H-Meso-1, MM-F1) and mouse 
(40 and #40a) MM cell lines were maintained in DMEM 
(Dulbecco’s modified Eagle’s medium) containing 10% 
fetal bovine serum, 100 U/ml penicillin and 100 µg/ml 
streptomycin (complete medium). The cells were grown 
at 37°C in a humidified incubator with an atmosphere of 
5% CO2. The #40a cell line derives from the 40 cell line 
after two passages in the peritoneal cavity of C57BL/6 
mice. These passages allow the selection of cells which 
reproducibly form ascites when intraperitoneally 
injected in the mice. H-Meso-1 cells have an epithelial 
morphology, while MM-B1 and MM-F1 cells have 
biphasic and sarcomatous features, respectively [74]. The 
40 cell line has an epithelial morphology [75].
CUR was dissolved in DMSO. For the treatments, 
the cells were incubated for the indicated times in the 
presence of CUR (dose range: 6.25-50 µM) or the vehicle 
(DMSO ≤ 0.1%).
Sulforhodamine B (SRB) assay
Cells were seeded at 5x103/well in 96-well plates 
and incubated at 37°C to allow cell attachment. After 24 
hours, the medium was changed and the cells were treated 
with CUR or DMSO and incubated for 24 hours, 48 hours, 
72 hours at concentrations of 6.25-12.5-25-50 µM. The 
cells were then fixed with cold trichloroacetic acid (final 
concentration 10%) for 1 hour at 4°C. After 4 washes with 
distilled water, the plates were air-dried and stained for 
30 min with 0.4% (wt/vol) SRB in 1% acetic acid. After 
4 washes with 1% acetic acid to remove the unbound 
dye, the plates were air-dried, and cell-bound SRB was 
dissolved with 200 µl/well of 10 mM unbuffered Tris base 
solution. The optical density (O.D.) of the samples was 
determined at 540 nm with a spectrophotometric plate 
reader. The percentage survival of the cultures treated with 
CUR was calculated by normalizing their O.D. values to 
those of control cultures treated with DMSO [20]. The 
experiments were performed in triplicate and repeated 
three times.
Fluorescent measurement of ROS
Dichlorofluorescin diacetate (DCF-DA) was used 
to detect ROS production in MM cells. Briefly, 2.5×105 
cells were seeded into 6-well plates and incubated at 
37 °C to allow cells attachment before treatment. After 
two washings with PBS, cells were incubated with 10 
μM 2′,7′-dichlorofluorescein diacetate (Sigma-Aldrich, 
Milan, Italy) in PBS at 37°C and 5% CO2 in the dark for 
30 min [76]. After two washings, cells were treated with 
CUR (6.25-50 µM) or DMSO in serum-free medium and 
incubated at 37°C and 5% CO2 in the dark for different 
times (15 min-4 hours). Then, adherent and suspended 
cells were harvested, centrifuged at 1250 rpm for 10 
min, and seeded in 96-well plates (100 μl per well). 
Fluorescence intensity was measured after 15 and 30 
min and after 1 and 4 hours using a spectrophotometric 
plate reader at an excitation wavelength of 495 nm and an 
emission wavelength of 535 nm. Because the highest level 
of fluorescence was detected at 30 min and it decreased 
back to the level of the control after 1 hour of CUR 
stimulation (data not shown), this experimental time was 
chosen for subsequent experiments.
FACS analysis
Asynchronized, log-phase growing cells (60% 
confluent, approximately 2.5x105/well in 6-well plates) 
were treated with CUR (6.25-12.5-25 µM) or DMSO in 
complete culture medium. Z-VAD-FMK was used at a 
final concentration of 40 µM for 2 hours before addition 
of CUR treatment. After 48 hours adherent as well as 
suspended cells were harvested, centrifuged at 1500 rpm 
for 10 min and washed twice with cold phosphate-buffered 
saline (PBS). The cell pellets were re-suspended in 70% 
ethanol and incubated for 1 hour at -20°C. The cells were 
then washed twice with cold PBS, centrifuged at 1500 
rpm for 10 min, incubated for 1 hour in the dark with 
propidium iodide (25 μg/ml final concentration in 0.1% 
citrate and 0.1% Triton X-100) and analyzed by flow 
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cytometry using a FACSCalibur cytometer with CellQuest 
software [77].
Preparation of cell lysates and western blotting
Approximately 1x106 cells were seeded in 100-mm 
tissue culture dishes 24 hours prior to the addition of 25 
μM CUR or vehicle. After 24 hours of incubation, the cells 
were harvested, washed twice with cold PBS and lysed in 
RIPA lysis buffer (Triton X-100 1%, SDS 0.1%, NaCl 200 
mM, Tris HCl 50 mM pH 7.5, PMSF 1 mM, and NaOV 1 
mM). After 30 min at 4°C, the mixtures were centrifuged 
at 12000 g for 15 min and the supernatants were analyzed 
by western blotting. For western blotting analysis, 50 μg 
of cell lysates were resolved in 10% SDS-PAGE and then 
transferred to nitrocellulose membranes. After blocking, 
the membranes were incubated with specific primary 
antibodies at 1-2 μg/ml concentrations overnight at 4°C. 
After being washed, the filters were incubated with goat 
anti-mouse or anti-rabbit IgG, peroxidase-conjugated 
antibodies and developed by chemiluminescence as 
previously described [78]. A densitometric analysis of 
autoradiographic bands was performed with Image J 
software (National Institutes of Health, USA) after blot 
scanning.
Immunofluorescence
Cells were seeded at 4x104 cells/well in 8-well 
chamber slides and, after 24 hours, they were treated with 
25 μM CUR, or with the vehicle. After 24 hours, the cells 
were fixed in 4% formaldehyde for 10 min, washed and 
fixed in methanol for 5 min at -20°C, then washed again 
and incubated with specific primary antibodies for 1 hour 
at room temperature. After additional washings, the cells 
were labeled with a goat anti-rabbit IgG Alexa fluor-594-
conjugated and goat anti-mouse IgG Alexa fluor-488-
conjugated secondary antibody for 30 min [79]. After 
a third washing, the cells were incubated with 0.1 μg/
ml Hoechst 33342 and mounted under a cover slip with 
glycerol. The cells were observed with an Olympus BX51 
microscope.
In vivo treatment of C57BL/6 mice 
intraperitoneally administered with CUR and 
transplanted with #40a cells
Groups of 6-to-8-weeks-old C57BL/6 mice (6 
mice per group) were intraperitoneally (i.p.) inoculated 
with 0.2 ml of suspension containing 1.5x106 #40a 
cells in phosphate-buffered saline (PBS) one week 
after pristane injection (500 µl). Mice were treated 
i.p. with CUR (1.5 mg dissolved in 800 µl of corn 
oil, 1 time per week), or corn oil (800 µl, 1 time per 
week). The treatments were started simultaneously 
with the inoculation of cells. Isolation of the murine 
mesothelioma 40 cell line was previously described 
by Goodglick et al. [75]. The #40a cell line is derived 
from the 40 cell line after two passages in the peritoneal 
cavity following administration of pristane one week 
before cell transplant. The intraperitoneal injection 
of a mineral oil such as pristane was shown to induce 
inflammation in mice [80].
Investigation has been conducted in accordance 
with the ethical standards and according to the 
Declaration of Helsinki. A veterinary surgeon was 
present during the experiments. The animal care both 
before and after the experiments was performed only 
by trained personnel. Mice were bred under pathogen-
free conditions in the animal facilities of the University 
of Rome “Tor Vergata” and handled in compliance 
with European Union and institutional standards for 
animal research. The work was conducted with the 
formal approval of the local animal care committees 
(institutional and national), and animal experiments have 
been registered as legislation requires (Authorization 
from Ministry of Health n° 187/2016-PR).
Analysis of antitumor activity in vivo
#40a cells growth in the peritoneum induces ascites. 
Accordingly, the abdominal circumference of mice was 
monitored before the inoculation of cells and every week 
until tumor-bearing mice were euthanized at the first 
signs of distress or when their abdominal circumference 
exceeded 12 cm.
Statistical analysis
The data distribution of cell survival and the FACS 
analyses were preliminarily verified by Kolmogorov-
Smirnov test, and data sets were analyzed by one-way 
analysis of variance (ANOVA) followed by Newman-
Keuls test. Differences in the intensity of immunoreactive 
bands were evaluated by a two-tailed Student’s t-test. 
Values with p≤ 0.05 were considered significant. Survival 
curves and tumor volumes were estimated using the 
Kaplan-Meier method and compared with a log-rank 
test (Mantel-Cox). Differences in tumor volumes were 
regarded as significant when the p value was ≤0.05 [81].
Abbreviations
DMSO, Dimethyl sulfoxide; PARP-1, Poly (ADP-
ribose) polymerase-1; ERK, extracellular signal-related 
kinase; p-ERK, phospho-ERK; p-AKT, phospho-AKT; 
MAPK, mitogen-activated protein kinase.
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